Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as C. difficile vaccine (previously studied formulation)., C. difficile vaccine
C.difficile vaccine · 1 trial · 1 indication
Injection site pain, redness, and swelling as self-reported in electronic diaries
Fever, vomiting, fatigue, headache, muscle pain, and joint pain as self-reported in electronic diaries
As elicited by investigator site staff
As elicited by investigator site staff
First episode of medically attended and clinically meaningful primary CDI incidence per 1000 person- years of follow- up
First episode of medically attended primary CDI incidence per 1000 person- years of follow- up
First episode of clinically meaningful primary CDI incidence per 1000 person- years of follow- up
| Arm | Type | Description |
|---|---|---|
| C.difficile vaccine | EXPERIMENTAL | Novel vaccine formulation |
| Saline Placebo | OTHER | - |
| Name | Type | Description |
|---|---|---|
| C.difficile vaccine | BIOLOGICAL | C.difficile vaccine given as an intramuscular injection |
| Saline Placebo | OTHER | 0.9% sodium chloride solution given as a intramuscular injection |
Who Can Join the Study (Inclusion Criteria): • People with recent or future planned contact with healthcare systems, recent antibiotic exposure, or a diagnosis of certain chronic medical conditions. Who Cannot Join the Study (Exclusion Criteria): * Anyone who has had CDI before. * Anyone who has ...
C. difficile vaccine is an investigational vaccine being developed to prevent Clostridium difficile associated disease, also referred to as Clostridioides difficile associated disease. It is intended for use in adults, with clinical studies evaluating regimens in healthy adults aged 50 to 85 years and in people 65 years of age and older.
C. difficile vaccine is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
C. difficile vaccine is in Phase 1 clinical development. Early-stage trials have been completed, and a Phase 3 study is currently recruiting participants. The vaccine remains investigational and is not yet approved for commercial use.
C. difficile vaccine has been studied in several clinical trials. Completed Phase 1 trials include NCT01706367 and NCT02052726, which evaluated 3-dose regimens in healthy adults aged 50 to 85 years. A Phase 3 trial, NCT07282665, is currently recruiting 32,500 participants aged 65 years and older.
Yes, C. difficile vaccine is also known as C.difficile vaccine. The alternative name refers to the same investigational vaccine developed by Pfizer, Inc. for the prevention of Clostridium difficile associated disease.